IDH1 and central nervous system cancer: Unlike the effect of IDH mutations on the outcomes of other cancers, patients with IDH-mutated gliomas generally have a more favorable prognosis than those with IDH-wild-type gliomas [1], but treating IDH-mutated gliomas with mutant IDH inhibitors is controversial [29].